Hematology/Oncology Section Bibliography

Hematology/Onoclogy Bibliography 2012

Hematology/Oncology Bibliography 2011

Hematology/Oncology Bibliography 2010

Books

Synder, Lois, JD: and for the American College of Physicians Ethics, Professionalism, and Human Rights Committee (López AM- Vice Chair) ACP Ethics Manual (sixth edition). Annals of Internal Medicine.
January 3, 2012- Volume 156, Number 1 (Part 2):pp. 73-104).

Ursa Brown-Glaberman, Alison T Stopeck. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics: Targets and Therapy 11, April 2012

Jha AK, Kupinski1 MA, RodríguezJJ, Stephen RM, Stopeck AT. Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard. Physics in Medicine and Biology. Volume 57 Number 13
 

Editorials

Alberts DS, Crano SL. “Personalized Medicine in Oncology: An oncologist and his patient team up to share their major success against all odds.” Southern California Clinician, 2012.

Jeter JM, Alberts DS. Difluoromethylornithine: The Proof is in the Polyamines. Cancer Prev Res (Phila). 2012 Dec. 5(12):1341-4.
 

Chapters

Chapters in scholarly books and monographs

Alberts DS; Stratton SP, Lance MP, Thompson P. Cancer Prevention slide set for the American Society of Clinical Oncology (in press, 2012).

Bermudez Y, Cordova K, Williams JD. Folate Nutrition in Skin Health and Skin Cancer Prevention. Bioactive Dietary Factors and Plant Extracts in Dermatology. 2012: Part V Chapter 22 Page 229-256. ISBN: 9781627031660

Larmonier N, Katsanis E. Dendritic Cells for Cancer Immunotherapy. Accepted In Emerging Trends in Cell and Gene Therapy Springer Science, New York / Heidelberg (in press)

Morgan SS, Jeter JM, Hersh EM,, YI SK, Cranmer LD. Management of Brain Metastasis in: Melanoma – From Early Detection to Treatment: edited by Guy Huynh Thien Duc, ISBN 978-953-51-0961-7, InTech, January 1, 2013

Morgan SS, Jeter JM, Hersh EM, Yi SK, Cranmer LD. Management of Brain Metastasis in Melanoma Patients. In Melanoma – From Early Detection to Treatment; InTech Europe; Rijeka, Croatia; Guy Huynh Thien Duc, ed. In press.

Hunt KS, Ray JA, Jeter JM. Hereditary Risk of Cancer. In Fundamentals of Cancer Prevention; Springer; Heidelberg, Germany; Alberts DA, Hess L, eds.; 3rd Edition. In press.

Weinstein R, López AM, Graham AR, Barker GR. Secrets to Success for Telemedicine and Telehealth Programs in The Thought Leaders Project: E-Health, Telemedicine, Connected Health—The Next Wave of Medicine. B. J. Bierbaum (Ed.). Bierbaum Publishing: Minneapolis, MN, 2012. 73-91.
 

Journal Articles

Frederick R. Ahmann, MD

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10. PubMed PMID: 22887343.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity. Intern Med J. 2012 Apr;42(4):374-80. doi: 10.1111/j.1445-5994.2011.02473.x. PubMed PMID: 21395960.

Algotar A.M., Thompson P. A., Ranger-Moore J., Stratton M.S., Hsu C.H., Ahmann F.R., Stratton S. P. Characteristics of subjects having high PSA velocity. Internal Medicine Journal 42:4:374 April 2012.

Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila). 2012 Feb;5(2):290-8. doi: 10.1158/1940-6207.CAPR-11-0306. Epub 2011 Nov 1. PubMed PMID: 22044694; PubMed Central PMCID: PMC3273617.

Tolcher, AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G., Drake T, Keating A, and De Bono JS: A Phase II study of YM155, a noval small-molecule suppressor of surviving, in castration-resistant Taxane- pretreated prostate cancer. Ann. Oncol. 2012 Apr:23(4):968-73. Doi: 10.1093/annonc/mdr353. Epub 2011 Aug 22. PMID 21859898.

David S. Alberts, MD

Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol. 2012 Dec;127(3):451-5. doi: 10.1016/j.ygyno. 2012.09.008. Epub 2012 Sep 14. PubMed PMID: 22986144.

Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK. Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer. Invest New Drugs. 2013 Feb;31(1):160-6. doi: 10.1007/s10637-012-9827-5. Epub 2012 May 13. PubMed PMID: 22580577.

Bartels PH, Bartels HG, Alberts DS, Yozwiak M, Prasad AR, Glazer ES, Krouse RS. Karyometry of nuclear phenotypes in cutaneous squamous cell cancer. AnalQuant Cytol Histol. 2012 Feb;34(1):1-8. PubMed PMID: 22590813.

Bartels PH, Garcia FA, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Alberts DS. Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr;125(1):129-35. doi:10.1016/j.ygyno.2011.12.422. Epub 2011 Dec 9. PubMed PMID: 22155796.

Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res. 2012 May 1;18(9):2668-78. doi: 10.1158/1078-0432.CCR-12-0261. Epub 2012 Mar 15. PubMed PMID: 22421191; PubMed Central PMCID: PMC3343173.

Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu CH, Nagle R, Sagerman P, Tangrea J, Parnes H, Alberts DS, Chow HH. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma:evaluation of potential chemopreventive activity. Cancer. 2012 Dec 1;118(23):5848- 56. doi: 10.1002/cncr.27540. Epub 2012 May 17. PubMed PMID: 22605570; PubMed Central PMCID: PMC3517927.

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellacani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF 3rd. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res (Phila). 2012 Mar;5(3):403-13. doi: 10.1158/1940-6207.CAPR-11-0427. Erratum in: Cancer Prev Res (Phila). 2012 Aug;5(8):1072. Pellicani, Giovanni [corrected to Pellacani, Giovanni]. PubMed PMID: 22389437; PubMed Central PMCID: PMC3297971.

Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control. 2012 Sep;23(9):1451-61. doi: 10.1007/s10552-012-0019-6. Epub 2012 Jul 5. PubMed PMID: 22763500; PubMed Central PMCID: PMC3416973.

Jeter JM, Alberts DS. Difluoromethylornithine: the proof is in the polyamines. Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429. PubMed PMID: 23221207.

Tang DH, Alberts DS, Nevins R, Sullivan S, Skrepnek GH. Health care expenditures, hospitalizations, and productivity associated with cancer in US employer settings. J Occup Environ Med. 2012 Dec;54(12):1453-60. doi: 10.1097/JOM.0b013e31827943e0. PubMed PMID: 23169275.

Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer Prev Res (Phila). 2012 Dec;5(12):1381-93.
doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11. PubMed PMID: 23060037;PubMed Central PMCID: PMC3518663.

Wertheim BC, Smith JW, Fang C, Alberts DS, Lance P, Thompson PA. Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. Cancer Prev Res (Phila). 2012 Feb;5(2):197-204. doi: 10.1158/1940-6207.CAPR-11-0320. Epub 2011 Nov 4. PubMed PMID: 22058145; PubMed Central PMCID: PMC3400261.

Catherine A. Azar, MD

Romond E, Jeong J-H, Rastori P, Azar C, et al: Seven-Year Follow-up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide (AC) followed by Paclitaxel to AC Followed by Paclitaxel Plus Trastuzumab as Adjuvant Therapy for Patients with Node- Positive, HER2-Positive Breast Cancer. JCO, 30(31): 3769-72, 2012.

Amanda F. Baker, PhD, PharmD

Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK. Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer. Invest New Drugs. 2013 Feb;31(1):160-6. doi: 10.1007/s10637-012-9827-5. Epub 2012 May 13. PubMed PMID: 22580577.

Baker AF, Adab KN, Raghunand N, Chow HH, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Invest New Drugs. 2012 Jun 19. [Epub ahead of print] PubMed PMID: 22711542.

Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012 Jul;41(5):773-81. doi: 10.1097/MPA.0b013e31823cdd10. PubMed PMID: 22273698; PubMed Central PMCID: PMC3337960.

Cárdenas-Rodríguez J, Li Y, Galons JP, Cornnell H, Pagel MD, Baker AF, Investigation of imaging biomarkers to monitor response to the hypoxia-activated prodrug. TH-302 in the MiaPaCa2 flank xenograft model. Magn Reson Imaging 2012 [Epub ahead of print]. PMID 22554971.

Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012 Jun;69(6):1487-98. doi: 10.1007/s00280-012-1852-8. Epub 2012 Mar 2. PubMed PMID: 22382881.

Stephen RM, Pagel MD, Brown K, Baker AF, Meuillet EJ, Gillies RJ. Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Exp Biol Med (Maywood). 2012 Nov 1;237(11):1273-80. doi: 10.1258/ebm.2012.011326. PubMed PMID: 23239438.

Jennifer W. Bea, PhD

Kabat GC, Kim MY, Jean-Wactawski-Wende, Bea JW, Edlefsen KL, Adams-Campbell LL, De Roos AJ, Rohan TE. Anthropometric factors, physical activity, and risk of non-Hodgkin's lymphoma in the Women's Health Initiative. Cancer Epidemiol. 2012 Feb;36(1):52-59. doi: 10.1016/j.canep.2011.05.014. Epub 2011 Aug 4. PubMed PMID:21816698.

Yira Bermudez, PH.D., M.P.H.

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellicani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, and Petricoin EF III. Functional Protein Pathway Activation Mapping of the Progression of Normal Skin to Squamous Cell Carcinoma. Cancer Prev Res 2012;5 403-413. PMID: 22389437

Maria C. Bishop, MD

Badger, T.A., Sergrin, C., Figueredo, A.J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., Bishop, M. "Who Benefits From a Psychosocial Counseling Versus Educational Intervention to Improve Psychological Quality of Life in Prostate Cancer Survivors?". Psychology and Health, 2012.

Michael A. Bookman, MD

Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar;55(1):96-113. doi: 10.1097/GRF.0b013e31824b45da. Review. PubMed PMID: 22343232.

Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May;125(2):421-6. doi: 10.1016/j.ygyno.2012.01.008. Epub 2012 Jan 16. PubMed PMID: 22261301; PubMed Central PMCID: PMC3490188.

Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retro- peritoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jan;124(1):53-8. doi: 10.1016/j.ygyno.2011.09.024. Epub 2011 Oct 26. PubMed PMID: 22032836.

Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Mar;124(3):575-81. doi: 10.1016/j.ygyno.2011.11.022. Epub 2011 Nov 21. PubMed PMID: 22112610; PubMed Central PMCID: PMC3278512.

Pavani Chalasani, MD, MPH

Gottlieb RH, Krupinski E, Chalasani P, Cranmer L. Quantified visual scoring of metastatic melanoma patient treatment response using computed tomography: improving on the current standard. J Digit Imaging. 2012 Apr;25(2):258-65. doi:10.1007/s10278-011-9407-9. PubMed PMID: 21785917; PubMed Central PMCID:PMC3295970.

Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2012 Mar 20. [Epub ahead of print] PubMed PMID: 22441342.

Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R. Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2012 Oct 11. [Epub ahead of print] PubMed PMID: 23053399.

Hsiao-Hui Sherry Chow, PhD

Chambers, S.K., Chow, H-H.S., Janicek, M.F., Cragun, J.M., Hatch, K.D., Cui, H., Laughren, C., Clouser, M.C., Cohen, J.L., Wright, H.M., Shahin, N.A., Alberts, D.S. Phase 1 trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clinical Cancer Research 18:2668-2678, 2012. PMID: 22421191; PMCID: 3343173

Curiel-Lewandrowski, C., Swetter, S.M., Einsphar, J.G., Hsu, C-H., Nagle, R., Sagerman, P., Tangrea, J.A., Parnes, H.L., Alberts, D.S., Chow, H-H.S. Randomized, double-blind, placebo controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity. Cancer 118:5848-5856, 2012. PMID:22605570

Dow, C.A., Going, S.B., Chow, H-H.S., Patil, B.S., Thomson, C.A. The effect of daily consumption of grapefruit on body weight, lipids, and blood pressure in healthy, overweight adults. Metabolism 61:1026- 1035, 2012. PMID: 22304836

Hakim, I.A., Harris, R.B., Garland, L.L., Cordova, C., Mikhael, D.M., Chow, H-H.S. Gender Difference in Systemic Oxidative Stress and Antioxidant Capacity in Current and Former Heavy Smokers. Cancer Epidemiology Biomarkers & Prevention 21:2193-2200, 2012. PMID:23033455

Miller, J.A., Thompson, P.A., Hakim, I.A., Lopez, A.M., Thomson, C.A., Chew, W., Hsu, C-H., Chow, H-H.S. Safety and feasibility of topical application of limonene as a massage oil to the breast. Journal of Cancer Therapy 3:749-754, 2012

Nguyen, M. M., Ahmann, F. R., Nagle, R. B., Hsu, C. H., Tangrea, J. A., Parnes, H. L., Sokoloff, M. H., Gretzer, M. B., Chow, H-H.S. Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities. Cancer Prevention Research 5: 290-8, 2012. PMID: 22044694; PMCID: 3273617

Thompson, P., Roe, D., Fales, L., Buckmeier, J., Wang, F., Hamilton, S.R., Bhattacharyya, A., Green, S.B., Hsu, C.H., Chow, H-H.S., Ahnen, D.J., Boland, C.R., Heigh, R.I., Fay, D.E., Martinez, E., Jacobs, E., Ashbeck, E.L., Alberts, D.S., Lance, P. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer Prevention Research 5:1381-1393, 2012. PMID: 23060037

Lee D. Cranmer, MD, PhD

Cranmer LD, et al. (2012) Phase II study of volociximab (M200), and α5β1 anti-integrin antibody in metastatic melanoma.

Cranmer LD, et al. (2012) A Phase I Study to Evaluate the Safety and Pharmacokinetics of Pro- 1, a Liposome-Encapsulated Thymidine Kinase Gene Formulation in Patients with Stage IV Metastatic Melanoma.

Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008- 5472.CAN-12-2194. Epub 2012 Aug 3. PubMed PMID: 22865454.

Curiel-Lewandrowski C, Speetzen LS, Cranmer LD, Warneke J, Loescher L. (2012) A casereport of Li-Fraumeni syndrome resulting in five malignant melanomas: clinico-pathological features of this rare entity and review of the literature.

Jeter JM, Cranmer LD, Hersh EM. Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol. 2012;6:275-86. doi:10.4137/CMO.S7245. Epub 2012 Jul 30. PubMed PMID: 22904648; PubMed Central PMCID:PMC3418148.

Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012 Jun;69(6):1487-98. doi: 10.1007/s00280-012-1852-8. Epub 2012 Mar 2. PubMed PMID: 22382881.

Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE. Radiation-induced sarcoma of the breast: a systematic review. Oncologist. 2012;17(3):405-18. doi:10.1634/theoncologist.2011-0282. Epub 2012 Feb 14. PubMed PMID: 22334455; PubMed Central PMCID: PMC3316927.

Janine G. Einspahr, PhD

Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Nagle R, Sagerman P, Tangrea J, Parnes H, Alberts DS, Chow C-HH. Randomized, Double-blind, Placebo Controlled Trial of Sulindac in Individuals at Risk for Melanoma: Evaluation of Potential Chemopreventive Activity. Cancer, May 17, 2012.

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellicani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF. Functional Protein Pathway Activation Mapping of the Progression of Normal Skin to Squamous Cell Carcinoma. Cancer Prevention Research, Mar;5(3):403-13, 2012.

Linda L. Garland, MD

Hakim IA, Harris R, Garland L, Cordova CA, Mikhael DM, Chow H-H. Gender Difference in Systemic Oxidative Stress and Antioxidant Capacity in Current and Former Heavy Smokers. Cancer Epid Biomarkers Prev 2012 Dec;21(12):2193-200. doi: 10.1158/1055-9965.EPI-12-0820. Epub 2012 Oct 2.

Evan M. Hersh, MD

Jeter JM, Cranmer LD, Hersh EM. Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol. 2012;6:275-86. doi:10.4137/CMO.S7245. Epub 2012 Jul 30. PubMed PMID: 22904648; PubMed Central PMCID:PMC3418148.

Joanne M. Jeter, MD

Jeter JM, Alberts DS. Difluoromethylornithine: the proof is in the polyamines. Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi:10.1158/1940-6207.CAPR-12-0429. PubMed PMID: 23221207.

Jeter JM, Cranmer LD, Hersh EM. Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol. 2012;6:275-86. doi:10.4137/CMO.S7245. Epub 2012 Jul 30. PubMed PMID: 22904648; PubMed Central PMCID:PMC3418148.

Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control. 2012 Sep;23(9):1451-61. doi:10.1007/s10552-012-0019-6. Epub 2012 Jul 5. PubMed PMID: 22763500; PubMed Central PMCID: PMC3416973.

Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter JM, Begg CB, Orlow I, Berwick M, Armstrong B, Kricker A, Marrett LD, Millikan RC, Culver HA, Zanetti R, Kanetsky PA, From L, Gruber SB for the GEM Study Investigators. Risk of Non-Melanoma Cancers Among CDKN2A Mutation Carriers. J Natl Cancer Inst. 2012 Jun 20;104(12):953-6. Epub 2012 Apr 24.

Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM. An Unusual BRCA Mutation Distribution in a High Risk Cancer Genetics Clinic; Familial Cancer; 2013 Mar;12(1):83-7.

Emmanuel Katsanis, MD

Bravo R, Pelayo-Katsanis LO, Shehab ZM, Katsanis E. Diagnostic and Treatment Challenges for the Pediatric Hematologist Oncologist in Endemic Areas for Coccidioidomycosis. J Pediat Hematol Onc 2012 Jul;34(5):389-94. PMID: 22510771

Centuori S, Larmonier C, LaCasse CJ, Hanke NT, Kartchner J, Janikashvili N, Trad M, Alizadeh D, Bonnotte B, Larmonier N. Katsanis E. Tumor-induced myeloid-derived suppressor cells impair the differentiation of CD4+CD25+FoxP3+ regulatory T cells from naïve CD4+CD25-FoxP3- T lymphocytes J Leukocyte Biol 2012 Epub 2012 Aug 13. PMID: 22891289

Hanke NT, Alizadeh D, Katsanis E, Larmonier N. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Accepted in Critical Reviews in Immunology

Kopp L, Gupta P, Pelayo-Katsanis L, Wittman B, Katsanis E. Late effects in adult survivors of pediatric cancer: A guide for the primary care physician. Am J Med 2012 Jul;125(7):636-41. Epub 2012 May 4. PMID: 22560808

Larmonier N, Bonnotte B, Katsanis E. Cytotoxic and antigen presenting functions of T helper-1- activated dendritic cells. Oncoimmunol 2012 Jul 1;1(4):566-568. PMID: 22754789

Sarah L. Kratz, MD

Feasibility of Tomotherapy-Based Image-Guided Radiotherapy for Small Cell Lung Cancer. Nam P. Nguyen M.D., Wei Shen M.D., Sarah Kratz M.D., Jacqueline Vock M.D, Paul Vos Ph.D., Vinh- Hung Vincent M.D., Lars Ewell Ph.D., Siyoung Jang, Ulf Karlsson M.D., Juan Godinez M.D., Melissa Mills B.S., Alexander Chi M.D.

Terry H. Landowski, PhD

Dorr RT, Samulitis BK, Wisner L, Han H, Zhao Y, Beroza P, Damodaran K, Igarashi S, Landowski TH, Von Hoff DD. Characterization of a membrane-active anti-tumor agent, UA8967. Invest New Drugs. 2012 Nov 23. [Epub ahead of print]PubMed PMID: 23179338.

Dorr RT, Wisner L, Samulitis BK, Landowski TH, Remers WA. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. Cancer Chemother Pharmacol. 2012 Apr;69(4):1039-49. doi: 10.1007/s00280-011-1784-8. Epub 2011 Dec 21. PubMed PMID: 22186884; PubMed Central PMCID: PMC3314130.

Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Mol Cancer Res. 2012 Mar; 10(3):392-400. doi:10.1158/1541-7786.MCR-11-0359. Epub 2012 Jan 24. PubMed PMID: 22275514; PubMedCentral PMCID: PMC3324333.

Robert B. Livingston, MD

Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430. Oncologist. 2012;17(2):179-87

Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM.. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012 Jun 25;2(1):34.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. N Engl J Med. 2012 Aug 2;367(5):435-44.

Ana Maria López, MD, MPH, FACP

Friedman AJ, Chen Z, Ford P, Johnson CA, Lopez AM, Shander A, Waters JH, van Wyck D. Iron deficiency anemia in women across the life span. J Women’s Health (Larchmt). 2012 Dec;21(12):1282-9. doi: 10.1089/jwh.2012.3713

Haley, J, Klewer, S, Barber, B, Meaney FJ, Donnerstein, R, Weinstein, R, Krupinksi, E, Warda, G, Lopez, AM, Lax, D. Remote diagnosis of congenital heart disease in Southern Arizona: comparison between tele-echocardiography and videotapes. Telemedicine and e-Health. December 2012, 18(10): 736- 742. doi:10.1089/tmj.2012.0037.

Miller, JA, Thompson, PA, Hakim, IA, Lopez, AM, Thomson, CA, Chew, W, Hsu, CH, Chow, HHS. Safety and Feasibility of Topical Application of Limonene as a Massage Oil to the Breast. Journal of Cancer Therapy. October 2012.

López, AM. “On Parsimonious Care and Patient Care.” Arizona Medicine. Summer 2012.

Badger, TA, Segrin, C, Hepworth, JT, Pasvogel, A, Weihs, K, Lopez, AM. Telephone-delivered health education and interpersonal counseling improve quality of life for Latinas with breast cancer and their supportive partners. Psychooncology. 2012 May 10 (Epub ahead of print).

Larkey, L.K., Herman, P.M, Roe, D.J., Garcia, F., López, AM, Gonzalez, J., Perera, P.N., Saboda, K. A Cancer Screening Intervention for Underserved Latina Women by Lay Educators. Journal of Womens Health (Larchmt). 2012 March 14, ( E pub ahead of print).

Daruka Mahadevan, MD, PhD

Agarwal A, Mahadevan D. Novel targeted therapies and combinations for the treatment of multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 2012 Aug 10. PubMed PMID: 22882073.

Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 2013 Jan 15;119(2):371-9. doi:10.1002/cncr.27733. Epub 2012 Jul 25. PubMed PMID: 22833464; PubMed Central PMCID: PMC3485430.

Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R. Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2012 Oct 11. PubMed PMID: 23053399.

Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2012 Mar 20. PubMed PMID: 22441342.

Mahadevan D, Periandy S, Karabacak M, Ramalingam S, Puviarasan N. Spectroscopic (FT-IR, FT- Raman and UV-vis) investigation and frontier molecular orbitals analysis on 3-methyl-2-nitrophenol using hybrid computational calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2012 Feb;86:139- 51. doi:10.1016/j.saa.2011.10.020. Epub 2011 Oct 19. PubMed PMID: 22074882.

Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer. 2012 Dec;48(18):3319-27. doi: 10.1016/j.ejca.2012.06.027. Epub 2012 Aug 23. PubMed PMID: 22921184.

Mahadevan D, Walter RP, Minto G, Gale TC, McAllen CJ, Oldman M. Combined femoral and sciatic nerve block vs combined femoral and periarticular infiltration in total knee arthroplasty: a randomized controlled trial. J Arthroplasty. 2012 Dec;27(10):1806-11. doi: 10.1016/j.arth.2012.05.018. Epub 2012 Jul 5. PubMed PMID: 22770852.

Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012 Apr 15;18(8):2210-9. doi: 10.1158/1078-0432.CCR-11-2413. Epub 2012 Feb 28. PubMed PMID: 22374334.

Ong E, Diven C, Abrams A, Lee E, Mahadevan D. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for palliative treatment of malignant ascites from gastrointestinal stromal tumours. J Palliat Care. 2012 Winter;28(4):293-6. PubMed PMID: 23413766.

Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12. PubMed PMID: 23153524.

Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. Epub 2011 Nov 19. PubMed PMID: 21796626.

Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr 15;118(8):2138-47. doi: 10.1002/cncr.26469. Epub 2011 Sep 1. PubMed PMID: 21887679.

Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutrė S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar;53(3):417-23. doi:10.3109/10428194.2011.618232. Epub 2011 Nov 15. PubMed PMID: 21879809.

Thomas P. Miller, MD

Friedberg J, Byrtek M, Link BK, Flowers CR, Taylor M, Hainsworth J, Cerhan JR, Zelenetz A, Hirata J, Miller TP. Effectiveness of first line management strategies for Stage 1 Follicular Lymphoma: analysis of the National LymphoCare Study. J clin Oncol 2012 Sept 20;30(27):3368-75 Epub 2012 Aug 20 PMID 22915662

Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. Aurora A inhibitor (MLN8237) plus Vincristine plus Rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012 Apr 15;18(8): 2210-9.Feb 28. Epub 2012 Feb 28 PMID 22374334

Mahadevan D. Unger JM, Spier CM, Persky DO, Young F, Leblanc M. Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013 Jan 15; 119(2):371-9 Doi 10.1002/cncr27733 Epub 2012 Jul 25. PMID 22833464

Nabhan C, Bytrek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Levy D, Link BK, Flowers CR. Racial and Ethnic Differences in Presentation and Management of Follicular Lymphoma in the United States: Report from the National LymphoCare Study. Cancer 2012 Oct 1:118(19):4842-50 doi: 10.1002/cncr.27513 Epub 2012 Mar 20 PMID 22434428

Persky DO, Dornan D, Goldman GH, Braziel RM, Fisher RI, LeBlanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012 Jun:97 (6): 937-24, Epub 2012 Jan 22 PMID 22271896

Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine- Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016 J Clin Oncol. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO. 2012-42.4101. Epub 2012 Dec 10 PMID: 23233710

Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 2012 Nov 12. doi:pii: S)145-2126 (12) 00429-8. 10.1016/j.leukres.2012.10.017. [epub ahead of print] PMID: 23153524

Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn JM, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 2012 Aug 9;120(6):1210-7. Epub 2012 June 25 PMID 22734071

Daniel O. Persky, MD, PhD

Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012 Apr 15;18(8):2210-9. doi: 10.1158/1078-0432.CCR-11-2413. Epub 2012 Feb 28. PubMed PMID: 22374334.

Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 2013 Jan 15;119(2):371-9. doi: 10.1002/cncr.27733. Epub 2012 Jul 25. PubMed PMID: 22833464; PubMed Central PMCID: PMC3485430.

Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012 Jun;97(6):937-42. doi: 10.3324/haematol.2011.050419. Epub 2012 Jan 22. PubMed PMID: 22271896; PubMed Central PMCID: PMC3366663.

Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. Epub 2011 Nov 19. PubMed PMID: 21796626.

Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12. PubMed PMID: 23153524.

Alison T. Stopeck, MD

Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics. 2012;6:89-99. doi: 10.2147/BTT.S20677. Epub 2012 Apr 12. PMID:22532777

Cleeland CS, Body JJ, Stopeck A, von moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K. Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013 Feb 15: 119(4): 832-8. Epub 2012 Sep 5.

Iannone M, Pennick L, Tom A, Cui H, Gilbert M, Weihs K, Stopeck AT. Prevalence of depression in adults with haemophilia. Haemophilia. 2012 Nov;18(6):868-74. doi: 10.1111/j.1365-2516.2012.02863.x. Epub 2012 May 30. PMID:22642565

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase 3 trials. Eur J Cancer 2012 Nov:48(16):3082-92.

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Bone- related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012 Sep 1;18(17):4841-9. Epub 2012 Aug 14.

Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2- overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24.PMID:22198412

Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 2012 Jun 13.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K. Cost- Effectiveness of Denosumab versus Zoledronic Acid for Prevention of Skeletal-Related Events in Patients with Solid Tumors and Bone Metastases in the United States. J Med Econ. 2012 Mar 12. [Epub ahead of print] PMID: 22409231 [PubMed - as supplied by publisher]

Stopeck AT, Unger JM, Rimsza LM, Leblanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012 Jun 25.

Steven P. Stratton, PhD

Algotar, A.M., Hsu, C.H., and Stratton, S.P. Selenium supplementation has no effect on serum glucose levels in men at high risk for prostate cancer. (submitted 2012, accepted to Journal of Diabetes in 2013).

Algotar, A.M., Stratton, M.S., Ahmann, F.R., Ranger-Moore, J., Nagle, R.B., Thompson, P.A., Slate, E., Hsu, C.H., Dalkin, B.L., Sindhwani, P., Holmes, M.A., Tuckey, J.A., Graham, D.L., Parnes, H.L., Clark, L.C., and Stratton, S.P. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high risk for prostate cancer. (accepted to The Prostate, 2012, in press 2013).

Algotar, A.M., Thompson, P.A., Ranger-Moore, J., Stratton, M.S., Hsu, C.H., Ahmann, F.R., Nagle, R.B., and Stratton, S.P. Differences in characteristics of men with localized prostate cancer who demonstrate low, intermediate or high PSA velocity. Intern Med J 42:374-380, 2012.

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellacani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF 3rd. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res. 2012; 5(3):403-13.

Andrew M. Yeager, MD

Gabrilove, J., Kantarjian, H.M., Erba, H.P., Claxton, D., Arellano, M., Lyons, R.M., Kovascovics, T., Craig, M., Douer, D., Maris, M., Petersdorf, S., Shami, P.J., Yeager, A.M., Eckert, S., Huebner, D., and Faderl, S. Clinical Characteristics of Older Patients with Acute Myelogenous Leukemia (AML) Who Respond to Single-Agent Clofarabine. Brit. J. Haematol., submitted for publication, 2012.

Lancet, J.E., Cortes, J.E., Hogge, D.E., Tallman, M.S., Kovacsovics, T.J., Damon, L.E., Solomon, S., Kolitz, J.E., Cooper, M., Yeager, A.M., Louie, A.C., and Feldman, E.J. Phase IIb, Multicenter, Randomized, Open Label Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients with Untreated AML 60-75 Years of Age. J. Clin. Oncol., submitted for publication, 2012.

Storb, R., Gyurkocza, B., Storer, B., Sorror, M.L., Blume, K., Niederwieser, D., Chauncey, T.R., Pulsipher, M.A., Petersen, F.B., Sahebi, F., Agura, E.D., Hari, P., Bruno, B., McSweeney, P.A., Maris, M.B., Maziarz, R.T., Langston, A.A., Bethge, W., Vindeløv, L., Franke, G.-N., Laport, G.G., Yeager, A.M., Hübel, K., Deeg, J., Georges, G.E., Flowers, M.E.D., Martin, P.J., Mielcarek, M.,Woolfrey, A.E., Maloney, D.G., and Sandmaier, B.M. Graft-vs.-Host Disease and Graft-vs.-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation. J. Clin. Oncol., in press, 2012.
 

Poster Presentations/Meeting Abstracts

Conference paper abstracts and poster abstracts

David S. Alberts, M.D.

Alberts DS, Garcia FAR, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Bartels PH. Karyometry in atypical endometrial hyperplasia: A Gynecologic Oncology Group Study, Proceedings of the American Association for Cancer Research, Volume 53, #4614, 2012.

Coleman RL, Moon J, Sood AK, Branham D, Bonebrake AJ, Anderson G, Alberts DS, Markman, M. Randomized phase II study of docetaxel plus vandetanib (V+D) versus docetaxel followed by vandetanib (DV) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. American Association for Clinical Oncology, 2012.

Tate WR, Skrepnek GH, Alberts DS. Advanced disease in ovarian cancer: Clinical and economic outcomes within hospital inpatient settings. International Society for Pharmacoeconomics and Outcomes Research, 2012.

Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, Alberts DS, Krouse RS. The proportion of atypical nuclei and the relative frequency of highly atypical nuclei determine aggressiveness in cutaneous squamous cell carcinoma. American College of Surgeons, 2012.

Bowden GT, Einspahr JG, Curiel C, Stratton SP, Dong Z, Petricoin EF and Alberts DS. Thirty-Five Years with Bowden and Alberts: Down the Molecularly-Targeted Road to Skin Cancer Prevention. 10th International Skin Carcinogenesis Conference, 2012.

Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, Alberts DS and Krouse RS. Quantitative Histopathology to Accurately Predict the Natural History of Newly Resected Skin Squamous Cell Carcinomas. 10th International Skin Carcinogenesis Conference, 2012.

Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, Alberts DS, Krouse RS. The Relative Frequency of Highly Aggressive Nuclei Determine Aggressiveness in Cutaneous Squamous Cell Carcinoma. American College of Surgeons 98th Annual Clinical Congress, Chicago, IL, 2012.

Raja FA, Counsell N, Colombo N, Parmar MK, Pfisterer J, Vergote IB, Gonzalez-Martin A, Alberts DS, Ledermann JA. Platinum combination chemotherapy versus platinum monotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized trials using individual patient data. ESMO, 2012. 

Catherine A. Azar, MD

Robidoux A, Tang G, Rastogi P, Azar C, et al: Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 30, (Suppl; abstract LBA506), 2012.

Jennifer W. Bea, Ph.D.
Wright NC, S Levis, Bea JW, Carbone LD, Cauley JA, Chen Z, Crandall CJ, Curtis JR, Jackson RD, Johnson KC, LaCroix AZ, Robbins JA, Stefanick ML, Watts NB, Wactawski-Wende J. Does Accounting for Bone Mineral Density Alter the Association Between Body Mass Index and Fracture? Annual WHI Investigators Meeting, Washington DC., May 3-4, 2012.

Martinez S, Misner S, Dixon D, Armstrong-Florian T, Whitmer E, Farrell V, Martinez C, Hartz V, Bea JW. Nutrition and Physical Activity Knowledge of UANN Participating 4th/5th Grade Students – A Pilot Survey, Research Frontiers in Nutritional Sciences Conference, Tucson, AZ, February 29 and March 1, 2012.

Maria C. Bishop, MD

Badger, T.A., Segrin, C., Figueredo, A.J., Harrington, J., Bishop, M.(2012). Who benefits from counseling vs. educational intervention to improve psychological quality of life in prostate cancer survivors? Accepted for the 2012 State of the Science Congress on Nursing Research, Sept 13-15, Washington, D.C.

Ramireddy Bommireddy, PhD

Bommireddy, R., Rimsza L. M., Besselsen, D.G. Characterization of a Novel Mouse Model for Human B-cell Lymphomas. Presented at the 99th AAI Annual Meeting held in May 2012 in Boston, MA.

Hsiao-Hui Sherry Chow, PhD

Miller, J.A., Want, E.J., Thompson, P.A., Lang, J.E., Lance, P., Keun, H., Chow, H-H.S. “Application of metabolomics to assess limonene-induced metabolic changes in breast cancer patients.” 2012 Research Frontiers in Nutritional Science Conference, Tucson, AZ, February 29-March 1, 2012.

Miller, J.A., Lang, J.E., Hsu, C-H., Ley, M., Waer, A., Cordova, C., Chow, H-H.S. “A pilot clinical study of limonene in women with early stage breast cancer: effects of short-term treatment on tissue limonene disposition and serum markers.” American Association for Cancer Research Annual Meeting, Chicago, IL, March 31-April 4, 2012.

Miller, J.A., Want, E.J., Thompson, P.A., Lang, J.E., Lance, P., Chow, H-H.S. “Application of metabolomics to assess limonene-induced metabolic changes in breast cancer patients.” American Association for Cancer Research Annual Meeting, Chicago, IL, March 31-April 4, 2012.

Lee D. Cranmer, M.D., PhD

Cranmer, LD “Ipilmumab Induced Granulomatous Interstitial Nephritis” 2 May 2012.

S. Chawla, K. Ganjoo, L. Cranmer, S. Schuetze, B. Van Tine, N. Somiah, A. Staddon, M. Milhem, B. Samuels, N. Federman, D. Reed, P. Reitschel, F. Recio, A. Lopez Pouza, N. Khushalani, H. Tawbi, D. Reinke, S. Saks, T. Pierce, C. Eng, G. Lorente, S. Kroll, W.D. Tap “Randomized Phase 3 , Multicenter, Open-label Study Comparing TH-302 in Combination with Doxorubicin vs.Doxorubincin Alone in Subjects with Locally Advanced Unrectable or Metastatic Soft Tissue Sarcoma”. ASCO June 2012.

Janine G. Einspahr, PhD

Bowden GT, Einspahr JG, Curiel C, Stratton SP, Dong Z, Petricoin EF, and. Alberts DS. Thirty-Five Years with Bowden and Alberts: Down the Molecularly-Targeted Road to Skin Cancer Prevention. 10th International Skin Carcinogenesis Conference (ISCC), Columbus, Ohio, June 21-24, 2012. Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, Alberts DS, Krouse RS. Validation of Quantitative Histopathology in Identifying Aggressive Cutaneous Squamous Cell Carcinoma. Accepted for a quick shot presentation at the 7th Annual Academic Surgical Congress in Las Vegas, NV, Feb 14-16, 2012.

Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, Alberts DS, Krouse RS. The proportion of atypical nuclei and the relative frequency of highly atypical nuclei determine aggressiveness in cutaneous squamous cell carcinoma. American College of Surgeons' 98th Annual Clinical Congress, Chicago, IL, September 30-October 4, 2012.

Glazer ES, Bartels PH, Prasad AR, Yozwiak ML, Bartels HG, Einspahr JG, Alberts DS, Krouse RS. Quantitative Histopathology to Accurately Predict the Natural History of Newly Resected Skin Squamous Cell Carcinomas. 10th International Skin Carcinogenesis Conference (ISCC), Columbus, Ohio, June 21- 24, 2012.

Evan M. Hersh, MD

Axel, H, DelVecchio, M Brown, MP, Kefford, R, Loquai, C, Testori, A Bhatia, S, Gutzmer, R Conry, R, Haydon, A, Robert, C, Clawson, A, Elias, I, Renschler, M, HERSH, EM Phase 3 Study of nab- Paclitaxel vs Dacarbazine in Chemotherapy-naïve Patients with Mestatatic Malignant Melanoma November 7, 2012 Society of Melanoma Research SMR Congress Nov. 11, 2012 OncLive Online Publication Nov. 26, 2012

Joanne M. Jeter, MD

Jeter JM, Han J, Martinez ME, Qureshi A, Alberts DA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ Health Study; 2012 Annual Paris Melanoma Conference; April 27, 2012; Paris, France.

Linda L. Garland, MD

Garland L, Ou S-H, Moon J, Mack P, Testa J, Tsao A, Wozniak A, Gandara D. SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). Proc ASCO, 2012.

Emmanuel Katsanis, MD

Janikashvili N, LaCasse C, Hanke N, Gautheron A, Trad M, Ciudad M, Katsanis E, Bonnotte B and Larmonier N. IFN-γ promotes mouse bone-marrow dendritic cell cytotoxic function through STAT-1. Annual congress on Dendritic Cells (Club Francophone des Cellules Dendritiques, CFCD), Pasteur Institute, Paris, France, December 2012.

Trad M, Janikashvili N, Fraszczak J, Larmonier C, LaCasse C, Alizadeh D, Centuori S, Bonnefoy F, Perruche S, Katsanis E, Larmonier N* and Bonnotte B*. Immunosuppressive function of tumor- inflitrating dendritic cells mediated by exto-enzyme CD39. Annual congress on Dendritic Cells (Club Francophone des Cellules Dendritiques, CFCD), Pasteur Institute, Paris, France, December 2012.

Terry H. Landowski, PhD

Betty Samulitis, Lee Wisner, Robert Dorr, Terry H. Landowski. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with characteristics of EMT. Proceedings of the American Association for Cancer Research; March 31-April 4, 2012, Chicago

Ana Maria López, MD, MPH, FACP

Lopez, AM, Valencia, A, Ryan J, El-Khayat, Y, Nunez, A (December 4-8, 2012). ePromotora: Increasing Promotora’s Access to Breast Cancer Electronic Resources. 2012 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX.

Delbridge, M.S., Pedersen, R.C., Salinas, E.H., Gonzalez, V.J., Lopez, A.M., Lee, E.M., Viscusi, R.K., Boye Ley, M.L., Waer, A.L., Hazard, L.J., Pandamouz, A., Lang, J.E. (June 1-5, 2012). Stage I-III Breast Cancer in Geriatric Patients. 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Viscusi, R.K., Cui, H., Pockaj, B.A., Salinas, E. Brown, G., LeBeau-Grasso, L., Gonzalez, V., Lopez, A.M., Ley, M., & Lang, J.E. (May 2-6, 2012). A Combined Institutional Review of Prognostic Factors in Locally Advanced and Inflammatory Breast Cancer. The American Society of Breast Surgeons 14th Annual Meeting, Phoenix, AZ.

Lopez, A.M., Webster, P., Major, J., Hanson, K., Weinstein, R. (April 29 - May 1, 2012). Integrating Telemedicine in the Medical School Curriculum. American Telemedicine Association 17th Annual International Meeting & Exposition, San Jose, CA.

Badger, T.A., Segrin, C., Hepworth, J.T., Pasvogel, A., Weihs, K., & Lopez, A.M. (2012, February). Telephone-Delivered Health Education and Interpersonal Counseling Improve Quality of Life for Latinas With Breast Cancer and Their Supportive Partners. American Psychosocial Oncology Society 9th Annual Conference, Miami, FL, February 23-25, 2012.

Lang, J., Viscusi, R., Ley, M., Waer, A., Lee, Ellyn, Gonzalez, V., Hazard, L., Lopez, A.M., Pandamouz, A., & Delbridge, M. (2012, February). Impact of Age on Tumor Characteristics and Predictors of Treatment Options for Stage I-IV Breast Cancer Patients.

Robbins, M. L., Mehl, M. R., Weihs, K. L., & López, A. M. (2012, January). The Daily Conversations of Couples Coping with Breast Cancer. Annual meeting of the American Psychosomatic Society, Athens, Greece.

Robbins, M. L., Mehl, M. R., López, A. M., & Weihs, K. L. (2012, January). Emotional Expression in the Daily Conversations of Couples Coping with Breast Cancer. Annual meeting of the Society for Personality and Social Psychology, San Diego, CA.

Robbins, M. L., Mehl, M. R., Weihs, K. L., & López, A. M. (2012, January). Naturalistic observation of emotional expression in the daily conversations of couples coping with breast cancer. Annual meeting of the Society for Personality and Social Psychology, San Diego, CA.

Weinstein, R.S., López, A.M., Graham, A.R., Barker, G.R. Secrets to Success for Telemedicine and Telehealth Programs. Applied Aspects of Telemedicine & Telehealth. ATA Fall Forum 2012, New Orleans, LA. September 9, 2012.

Thomas P. Miller, MD

Mahadevan D, Cooke L, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. University of Arizona Cancer Center, University of Tennessee/West Clinic, University of Rochester. Alisertib plus rituximab is synergistic and synthetic lethal with vincristine in double hit ABC-diffuse large B-cell lymphoma. American Society of Hematology, 2012

Persky DO, Berstein SG, Goldman BH, Rimsza LM, Fisher RI, Miller TP. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. J Clin Onc (ASCO Annual Meeting) 30 No 15 suppl 4: Abstract #e18536, 2012.

Press OW, Unger JM, LeBlanc M, Rimsza LM, Friedberg J, Czuczman MS, Kaminski MS, Braziel RM, Spier C, Maloney DG, Cheson BD, Miller TP, Fisher RI. A Prognostic Factor and Subset Analysis of Protocol S0016, A Phase III Randomized Intergroup Trial Comparing CHOP Chemotherapy Plus Rituximab Vs. CHOP Plus Iodine-131-Tositumomab for Front-line Treatment of Follicular Lymphoma. J

Clin Onc (ASCO Annual Meeting) 30 No 15, suppl 4: Abstract # 8001, 2012. American Society of Hematology, 2012

Alison T. Stopeck, MD

K Chung, A Stopeck, M Danese, Z Cong, M Halperin, Y Qian, A Braun. Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-Related Events (SREs) in Patients with Breast Cancer and Bone Metastases (BM). Poster presention at the 8th Annual Hematology/Oncology Pharmacy Association conference, Salt Lake City, Utah, March, 2012.

R de Boer, M Martin, GG Steger, R von Moos, A Stopeck, K Tonkin, G Rodriguez, H Bourgeois, K Inoue, B Ding, K Chung, A Braun. A number-needed-to-treat analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases. Poster presentation at the International Symposium on Oncology Pharmacy Practice, Melbourne, Australia, May, 2012.

M Marron, A Stopeck. Microparticle generation and activation after treatment with paclitaxel and bavituximab combination therapy in metastatic breast cancer. Poster presentation at the Annual meeting of the American Association for Cancer Research, Chicago, IL, April, 2012.

LS Matza, Z Cong, K Chung, A Stopeck, K Tonkin, J Brown, A Braun, K Van Brunt, K McDaniel. Health State Preferences Associated with Subcutaneous Injections and Intravenous Infusions for Treatment of Bone Metastases. Poster presentation at the Annual meeting of the American Society of Clinical Oncology, Chicago, IL, June, 2012.

AT Stopeck, A Lipton, M Martín, JJ Body, A Paterson, GG Steger, K Tonkin, R de Boer, Y Fujiwara, D Yardley, J Jassem, T Takano, P Solal-Celigny, M Fan, A Braun. Results From the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study of Denosumab in Patients with Breast Cancer and Bone metastases Previously Treated with Zoledronic Acid or Denosumab. Oral Presentation at the Asian Oncology Summit, Singapore, April 2012.

AT Stopeck, G Richardson, S Siena, A Lipton, J Brown, K Fizazi, D Henry, F Saad, C Ke, A Braun. Denosumab versus zoledronic acid for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM) secondary to solid tumours: an integrated analysis of three phase 3 studies. Poster presentation at the Asian Oncology Summit, Singapore, April 2012.

Steven P. Stratton, PhD

Bowden, G.T., Einspahr, J., Curiel, C., Stratton, S.P., Dong, Z., Petricoin, E., Alberts, D. Thirty-Five Years with Bowden and Alberts: Down the Molecularly-Targeted Road to Skin Cancer Prevention. 10th International Conference on Skin Carcinogenesis, Columbus, OH, June, 2012.

Pin, E., Stratton, S.P., Silvestri, A., Belluco, C., Liotta, L., Nagle, R., Petricoin, E., and Pierobon, M. Pathway mapping of prostate cancer epithelium and stroma reveals new potential prognostic and therapeutic biomarkers. Human Proteome Organisation 11th Annual World Congress, Boston, MA, September 9-13, 2012.

Williams, J.D., Alvarez, I., Wondrak, G.T., and Stratton, S.P. Quantifying Reactive Carbonyl Species Toward the Chemoprevention of UV-Induced Skin Cancer. American Society of Preventive Oncology Annual Meeting, Washington, DC, March, 2012.

Andrew M. Yeager, MD

Lill, M., Costa, L.J., Yeh, R.F., Lim, S., Stuart, R., Waller, E.K., Shore, T., Craig, M., Freytes, C.O., Shea, T.C., Rodriguez, T.E., Flinn, I., Comeau, T., Yeager, A.M., Pulsipher, M. A., Bence-Bruckler, I., Laneuville, P., Bierman, P.J., Chen, A.I., Yu, L.H., Patel, S., Sun, Y., Armstrong, E., Smith, A., Elekes, A., Kato, K., and Vaughan, W. Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings from a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America. Biol. Blood Marrow Transplant., submitted, 2013.


Other Publications

Book reviews, commentaries, editorials or other non-refereed scholarly material, etc. 

Emmanuel Katsanis, MD: Katsanis E, Larmonier N. Combining cancer vaccines and T lymphocyte modulation. World Hell Biomed News 2012 Jan 3(1):10-14


Audio Interviews
 

Bea JW and Clark A. The Researcher and the Coach, Act Against Cancer Radio Show, Episode 49. 104.1FM: The Truth. March 25, 2012.

Ana Maria López, MD, MPH, FACP
Telemedicine
Clinical Applications. Rural Health Professions Program. Tucson, AZ February 22, 2012.

“Clinical Applications.” Developing a Telemedicine Program, Training Conference, September 24, 2012, Tucson, AZ.

Telemedicine Overview, guest lecture. University of Arizona College of Medicine. August 17, 2012.

Overview of Successful Telemedicine Programs and Clinical Applications, guest lecture. Public Health and Rural Policy Analysis. University of Arizona Mel and Enid Zuckerman College of Public Health. April 10, 2012.

Telemedicine Overview on Clinical Applications, videoconference. Telemedicine Interest Group, College of Medicine-Phoenix, AZ. February 17, 2012

Webinar Series Presented by The Arizona Telemedicine Program, The Southwest Telehealth Resource Center & The University of Arizona Center for Rural Health: Improving Access to Quality Medical Care, “Telediabetes & ADVICE: The Arizona Diabetes Virtual Center for Excellence,” March 14, 2012. Lopez, AM and Major, J.
 

Online

Berenson JR and Stopeck AT. Risks of Therapy with Bone Modifying Agents in Patients with Advanced Malignancy. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2012. Online at http://www.uptodate.com.

 

Web Pages

Bishop, Maria C CEPEC - Comprehensive Education in Palliative/End of Life Care (www.cepec.arizona.edu)

Lopez, Ana Maria Arizona Telemedicine Program (APT) site (http://www.telemedicine.arizona.edu